Emerging data suggests that retatrutide, a dual-action medication, could represent a significant step in body loss . This treatment combines the properties of a GLP-1 receptor and a GIP receptor , seemingly offering a enhanced outcome than existing approaches . Patient research have demonstrated promising findings , including substantial decreases